http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
류한영,설정현,김정철,한승세,우상현,최시호 大韓成形外科學會 1991 Archives of Plastic Surgery Vol.18 No.2
Bronchopleural fistula and chronic empyema are the difficult problems in the thoracic surgery field. We experienced 3 cases of chronic empyema and complicated bronchopleural fistulas treated with muscle flap and concomitant thoracoplasty. The causative primary diseases were pulmonary tuberculosis and bronchiectasis. All the three cases have failed to control the chronic empyema and bronchopleural fistula with conventional method such as closed or open drainage and Eloesser flap after lobectomy. The unresponsive infection on bronchopleural fistula and pleural space was well controlled after muscle flap with thoracoplasty. Complete decortication, closure of bronchopleural fistula as much as possible and coverage of closed fistula with good vascularized tissue are the essential factors for the success of operation on chronic empyema and bronchopleural fistula. The results of operations were satisfactory and the respiratory function was well preserved or improved in one patient. But, the contour of chest wall was deformed in patient with extensive concomitant thoracoplasty.
Sae WOO Han,Ok Joon Kim,Youn young Jang,Won Bong Lim,Oh Won Mann,Jin Soo Park,Myung Rae Kim,Hong Ran Choi 대한구강악안면병리학회 2004 대한구강악안면병리학회지 Vol.28 No.4
μ방lt emitting diodes (LED) devices are commercially introduced as an alternative for low-Ievellaser therapy (11ι,T) , and it has several advantages over lasers such as a safe, efficient, and less-expensive altemative to treat wounds. And LED irradiation at the same biostimulatory wavelength has similar bíochemical effεαs. In the present study, to asses whether the I핑ht-emitting diode (LED) irradíation can stimulate bone regeneration, irradiated bony defects with or without grafting materials on rat calvaria were compared to corresponding nonirradiated control. Fifty male Sprague-Dawly rats weighing about 150g, were used. Factors for present study were designed as follows, 1) presence or absence of grafting materials, 2) with or without irradiation, and 3) number of irradiation. Two weeks after operation, rats were sacrifìced. Radiologic and 비stomorphologic fmdings were evaluated. Macrospically, there were no incidents of infection, dehiscence, hematoma and necrosis during study. Radiological findings showed greater radiopacity in the graft group and radiopacity increased as the number of irradiation increase. And microscopically, new bαle formation was great in the graft group and increased as the number of irradiation increase, Present study has shown that LED irradiation improved bone regeneration through radiologic and histomorphologic fmdings in rat.
Powder injection molding process for fabrication of piezoelectric 2D array ultrasound transducer
Han, Jun Sae,Gal, Chang Woo,Park, Jae Man,Kim, Jong Hyun,Lee, Seung Hee,Yeo, Bong Whan,Lee, Baik Woo,Park, Sung Sik,Park, Seong Jin IOP 2018 Smart materials & structures Vol.27 No.7
<P>Powder injection molding process has been developed for a cost-effective fabrication of micro PZT array in diagnostic 2D array ultrasound transducer. The developed process consists six main steps; mold insert fabrication, mixing of powder and binder, injection molding, demolding of sacrificial mold insert, solvent and thermal debinding, densification of PZT ceramics. 1–3 type PZT/polymer composite fabricated by developed process shows 0.67 of electromechanical coupling property in plain mode and 0.56 in rod array mode which are 99% and 96% of reference property. Based on high productivity and shape complexity of ceramic injection molding, micro-manufacturing process for micro-scale PZT transducer has been demonstrated with according piezoelectric performance characterization.</P>
Jin Woo Jun,Sib Sankar Giri,Hyoun Joong Kim,Sae kil Yun,Cheng Chi,Sang Guen Kim,Sang Wha Kim,Jeong Woo Kang,Se Jin Han,Jun Kwon,Woo Taek Oh,Dal sang Jeong,Se Chang Park 한국예방수의학회 2018 예방수의학회지 Vol.42 No.3
In the current study, a total of 102 common Todarodes pacificus squid caught in the East Sea were investigated for parasitological research. The results revealed that 33 (32.35%) out of 102 squid were infected by Nybelinia surmenicola, the mean intensity was 5.58 parasites per squid, and the maximum abundance was 11. Morphological analysis using a field emission scanning electron microscope showed the characteristic features of N. surmenicola. Molecular identification based on the 28S rRNA gene confirmed the isolated parasite as N. surmenicola, while phylogenetic analysis revealed that N.surmenicola isolated in this study was clustered with N. surmenicola isolated from Japan. This is the first report of phylogenetic characterization of N. surmenicola isolated from Korea.
Genetic heterogeneity of liver cancer stem cells
Minjeong Kim(Minjeong Kim),Kwang-Woo Jo(Kwang-Woo Jo),Hyojin Kim(Hyojin Kim),Myoung-Eun Han(Myoung-Eun Han),Sae-Ock Oh(Sae-Ock Oh) 대한해부학회 2023 Anatomy & Cell Biology Vol.56 No.1
Cancer cell heterogeneity is a serious problem in the control of tumor progression because it can cause chemoresistance and metastasis. Heterogeneity can be generated by various mechanisms, including genetic evolution of cancer cells, cancer stem cells (CSCs), and niche heterogeneity. Because the genetic heterogeneity of CSCs has been poorly characterized, the genetic mutation status of CSCs was examined using Exome-Seq and RNA-Seq data of liver cancer. Here we show that different surface markers for liver cancer stem cells (LCSCs) showed a unique propensity for genetic mutations. Cluster of differentiation 133 (CD133)-positive cells showed frequent mutations in the IRF2, BAP1, and ERBB3 genes. However, leucine-rich repeat-containing G protein-coupled receptor 5-positive cells showed frequent mutations in the CTNNB1, RELN, and ROBO1 genes. In addition, some genetic mutations were frequently observed irrespective of the surface markers for LCSCs. BAP1 mutations was frequently observed in CD133-, CD24-, CD13-, CD90-, epithelial cell adhesion molecule-, or keratin 19-positive LCSCs. ASXL2, ERBB3, IRF2, TLX3, CPS1, and NFATC2 mutations were observed in more than three types of LCSCs, suggesting that common mechanisms for the development of these LCSCs. The present study provides genetic heterogeneity depending on the surface markers for LCSCs. The genetic heterogeneity of LCSCs should be considered in the development of LCSC-targeting therapeutics.
The Inhibitory Effect of Lorcaserin on Non Alcoholic Fatty Liver Disease in Animal Model
( Han Seul Park ),( Jae Young Jang ),( Seoung Won Jeong ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Sang-woo Cha ),( Young Seok Kim ),( Young Deok Cho ),( Hong Soo Kim ),( Boo Sung Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Nonalcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of liver damage spanning steatosis, nonalcoholic steatohepatitis, and liver cirrhosis. The aim of this study is to investigate the efficacy of lorcaserin on NAFLD in animal model. Methods: The leptin receptor deficient db/db mice and control mice (db/m) were fed a diet deficient in methionine and choline (MCD diet) and control diet for 8, respectively. Twenty mice were divided into 3 groups. The first group was fed a control diet without treatment and referred as the control group. The second group was administered with MCD diet +0.7% DMSO. The third group was administered with MCD diet +0.7% DMSO +5mg/ml of lorcaserin. Change of body weight was observed and blood was collected before sacrifice. After being sacrificed, the liver tissues were collected and fixed in formalin. Histological evaluation was evaluated by blindly pathologist. Results: The body weight of control mice was increased during the study, whereas feeding db/db mice MCD diets for 8 weeks significantly reduced in body weight. Lorcaserin treated group was associated with more rapid body weight loss compared with DMSO-treated controls. MCD diet induced excessive fat accumulation, inflammation, and some fibrosis. Liver enzyme and triglyceride were improved in lorcaserin-treated group compared with DMSO-treated control (DMSO vs lorcaserin: AST 411.3 ±40.26 vs 304.7 ±28.88 (U/L), ALT 544.8 ±38.7 vs 434.5 ±29.68 (U/L), triglyceride 31.8 ±2.02 vs 26 ±1.58 (mg/dL)). Liver histopathology showed that the fat accumulation and inflammatory cell infiltration were decreased in MCD diet +lorcaserin-treated mice compared with MCD diet +DMSO-treated controls. Conclusions: These results showed beneficial effects of lorcaserin against excessive fat accumulation and inflammation as well as liver enzyme. Therefore, our findings indicate that lorcaserin could be contributing to the decline of progression of nonalcoholic fatty liver disease.
The Limitation of Making Hepatic Fibrosis in NAFLD Animal Model
( Han Seul Park ),( Jae Young Jang ),( Soung Won Jeong ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Sang-woo Cha ),( Young Seok Kim ),( Young Deok Cho ),( Hong Soo Kim ),( Boo Sung Kim ),( So Young Jin ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Animal models of NAFLD give crucial information, not only pathogenesis of NAFLD but also therapeutic effects of various agents. We investigated the degree of steatosis, inflammation and fibrosis of the liver obtained from three animal models of NAFLD with different mouse species and diets. Methods: Group1: The mice were fed a control diet. Group2: The gene responsible for the production of leptin deficient ob/ob mice fed a 60% fat diet. Group3: The leptin receptor deficient db/db mice were fed a diet deficient in methionine and choline (MCD) diet. Group4: The leptin receptor deficient db/db mice were fed a 60% fat + 2.5% cholesterol diet and drinking water (55% fructose, 45% glucose w/w). Change of body weight was observed and blood was collected before sacrifice. After being sacrificed, the liver tissues were collected and fixed in formalin. Histological evaluation was conducted by blindly pathologist. Results: The body weight in group1 & 2 & 4 (control & high-fat-diet fed mice) were increased during the study, whereas group3 (MCD feeding mice) showed weight loss for unclear reasons. Liver histology showed no significant difference in hepatic steatosis and inflammation among the three groups (group2-4). Meanwhile, liver fibrosis was slightly more frequent in group3 than that in groups2 and 4. However, the maximum degree of fibrosis in group3 was Ib. The level of liver enzyme showed no significant difference, whereas the level of triglyceride was significantly increased in group4 (TG: 30.8±3.2 (group1), 31.8±4.9 (group2), 32.8±1.7 (group3), 141±15.20 (group4) (p < 0.001) (mg/dL)). Conclusions: The results show that the three animal models are thought to induce hepatic steatosis and inflammation very well, but the induction of hepatic fibrosis is still considered to be limited. A better animal model development or integration model would be needed.
( Sae Hwan Lee ),( Il Han Song ),( Ran Noh ),( Ha Yan Kang ),( Soon Young Ko ),( Eom Seok Lee ),( Seok Hyun Kim ),( An Na Kim ),( Byung Seok Lee ),( Hee Bok Chae ),( Hong Soo Kim ),( Young Woo Kang ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Backgroud/Aims: Sorafenib, an oral multikinase inhibitor with antiangiogenic and antiproliferative properties, showed significant benefits in terms of time to progression and survival in patients with advanced hepatocellular carcinoma (HCC) in large clinical trials. The aim of this study was to investigate treatment outcomes of sorafenib in real clinical fields. Methods: From August 2007 to March 2012, patients with advanced HCC who received sorafenib in seven referral hospitals in Daejeon-Chungcheong province were retrospectively enrolled for the evaluation of tolerability, treatment response and survival following sorafenib administration. Treatment response was radiologically assessed by RECIST 1.1. Results: Among a total of 123 patients enrolled, sixty-eight (55%) patients received prior treatment and 74 (60%) patients had Child-Pugh A cirrhosis. One hundred-three (84%) patients were BCLC stage C; Ninety-three (76%) patients were modified UICC IV. The median duration of sorafenib treatment was 67 (14-452) days. Seventy-three (60%) patients have experienced adverse events, resulting in transient dose reduction or cessation. Treatment interruption was brought by disease progression (36%), adverse events (21%), hepatic failure (10%), and financial burden (7%). Complete response, partial response and stable disease were seen in none, 1% and 18%, respectively, and disease control rate was 29%. Median time to progression was 84 days and overall median survival was 139 days. Patients with decompensated cirrhosis showed a shorter median time to progression (61 vs. 104 days, p=0.036) and overall survival (63 vs. 168 days, p<0.001) compared to those with compensated cirrhosis. Child-Pugh class B/C (p=0.027) and prior treatment (p=0.015) were independent risk factors for survival. Conclusions: Clinical outcomes of sorafenib treatment in patients with advanced HCC were comparable to those of previous studies. The function of hepatic reserve and history of previous treatment were independent factors affecting survival.